A Phase 2 interventional study of P03277 in Central Nervous System Indication, Pediatric Patients and Body Indication, sponsored by Guerbet. Completed at 16 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach.
The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of 0.05 mmol/kg body weight (BW) in pediatric population aged from 2 to 17 years undergoing CNS contrast-enhanced MRI (CNS cohort).
A population PK approach and an age-down staggered approach will be used. Patients will be recruited into 3 predefined age groups: 12-17, 7-11 and 2-6 years. The inclusions will start with the older group (Adolescents, 12-17 years), followed by Preadolescents (7-11 years) and finally Young Children (2-6 years of age).
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
To be included in the study, the patient had to meet all the following criteria:
Non-inclusion Criteria:
Patients could not be included in the study if they presented with one or more of the following non-inclusion criteria:
Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
Drug: P03277
Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
Drug: P03277
Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
Drug: P03277
Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
Drug: P03277
Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
Drug: P03277
Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
Drug: P03277
A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
Also known as: gadopiclenol
Elimination Half-life
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Total Clearance
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Central Volume of Distribution
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Peripheral Volume of Distribution
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Area Under the Curve
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Simulated Concentrations 10 Minutes Post-injection
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 10 minutes post-injection
Simulated Concentrations 20 Minutes Post-injection
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 20 minutes post-injection
Simulated Concentrations 30 Minutes Post-injection
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
Time frame: 30 minutes post-injection
| Milestone | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years |
|---|---|---|---|
| Started | 26 | 23 | 31 |
| Completed | 26 | 23 | 31 |
| Not completed | 0 | 0 | 0 |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| hours | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Elimination Half-life | 1.29 (0.69 to 3.38) | 1.48 (0.83 to 3.20) | 1.77 (1.00 to 3.57) |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| L/h/kg | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Total Clearance | 0.12 (0.05 to 0.28) | 0.10 (0.04 to 0.24) | 0.08 (0.04 to 0.20) |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| L/kg | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Central Volume of Distribution | 0.12 (0.06 to 0.26) | 0.12 (0.06 to 0.24) | 0.11 (0.05 to 0.24) |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| L/kg | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Peripheral Volume of Distribution | 0.06 (0.06 to 0.06) | 0.06 (0.06 to 0.06) | 0.06 (0.06 to 0.06) |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| mg.h/L | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Area Under the Curve | 403.16 ± 93.35 | 477.25 ± 105.71 | 582.30 ± 122.08 |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| mg/L | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Simulated Concentrations 10 Minutes Post-injection | 302.11 ± 44.68 | 327.20 ± 47.95 | 349.15 ± 52.59 |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| mg/L | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Simulated Concentrations 20 Minutes Post-injection | 234.88 ± 30.18 | 259.67 ± 32.02 | 285.16 ± 35.35 |
P03277 pharmacokinetic parameters in plasma were determined from the population PK model. This outcome was assessed only for the CNS cohort.
| mg/L | CNS Cohort 2-6 Years | CNS Cohort 7-11 Years | CNS Cohort 12-17 Years |
|---|---|---|---|
| Simulated Concentrations 30 Minutes Post-injection | 188.26 ± 25.10 | 211.20 ± 25.82 | 237.25 ± 26.97 |
Collected over Adverse events were recorded from informed consent signature untill the end of the study (up to 120 days after gadopiclenol administration).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CNS & Body Cohorts 2-6 Years | 0/26 (0%) | 1/26 (3.8%) | 4/26 (15.4%) |
| CNS & Body Cohorts 7-11 Years | 0/23 (0%) | 0/23 (0%) | 6/23 (26.1%) |
| CNS & Body Cohorts 12-17 Years | 0/31 (0%) | 2/31 (6.5%) | 4/31 (12.9%) |
| Event | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years |
|---|---|---|---|
| Head injuryInjury, poisoning and procedural complications | 1/26 | 0/23 | 0/31 |
| EpilepsyNervous system disorders | 1/26 | 0/23 | 0/31 |
| ComaNervous system disorders | 1/26 | 0/23 | 0/31 |
| Condition aggravatedGeneral disorders | 1/26 | 0/23 | 1/31 |
| HydronephrosisRenal and urinary disorders | 0/26 | 0/23 | 1/31 |
| TonsillitisInfections and infestations | 0/26 | 0/23 | 1/31 |
| Event | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years |
|---|---|---|---|
| PharyngitisInfections and infestations | 0/26 | 1/23 | 0/31 |
| Tracheobronchitis mycoplasmalInfections and infestations | 0/26 | 1/23 | 0/31 |
| Upper respiratory tract infectionInfections and infestations | 0/26 | 1/23 | 0/31 |
| Condition aggravatedGeneral disorders | 0/26 | 1/23 | 0/31 |
| Blood pressure increasedInvestigations | 0/26 | 1/23 | 0/31 |
| Eosinophil count increasedInvestigations | 0/26 | 1/23 | 0/31 |
| Neutrophil count decreasedInvestigations | 0/26 | 1/23 | 0/31 |
| EpilepsyNervous system disorders | 0/26 | 1/23 | 0/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/26 | 1/23 | 0/31 |
| PruritusSkin and subcutaneous tissue disorders | 0/26 | 1/23 | 0/31 |
All patients who received gadopiclenol administration and underwent CNS or Body MRI
| Age, Continuous(years) | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years | Total |
|---|---|---|---|---|
| Mean | 3.8 ± 1.3 | 8.8 ± 1.2 | 14.3 ± 1.6 | 9.3 ± 4.6 |
| Sex: Female, Male(Participants) | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years | Total |
|---|---|---|---|---|
| Female | 7 | 13 | 19 | 39 |
| Male | 19 | 10 | 12 | 41 |
| Ethnicity (NIH/OMB)(Participants) | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 26 | 23 | 31 | 80 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CNS & Body Cohorts 2-6 Years | CNS & Body Cohorts 7-11 Years | CNS & Body Cohorts 12-17 Years | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 26 | 23 | 31 | 80 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Dec 2019, 13 months.
Results were first posted in Jun 2022, 2 years 5 months after primary completion. A results delay was requested in Aug 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol